Listed by the USPTO as KIM, TAEYOON
Tech Center 1600 • Art Units: 1631 1632 1641 1651
This examiner grants 51% of resolved cases
Taeyoon Kim is a USPTO patent examiner in tech center 1600 and art unit 1631. Across 901 resolved cases, the allowance rate is 51.2%, the interview lift is 52.1%, and the median time to allowance is 1382 days. The profile indicates a demanding allowance environment in which interviews have a substantial recorded association with successful outcomes.
The listed companies are The Regents of the University of California, University of Louisville Research Foundation Inc., and Intellia Therapeutics Inc. Representative firms include ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP, FISH & RICHARDSON P.C. (TC), and ALSTON & BIRD LLP. Practitioners may benefit from early interview planning paired with carefully supported claim amendments.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17611497 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | Final Rejection | Merck Patent GmbH |
| 18713196 | ESTABLISHMENT OF ERYTHROID PRECURSOR CELL LINE CAPABLE OF CONDITIONAL MATURATION USING GENE OVEREXPRESSION | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18701379 | METHOD FOR SUSPENSION CULTURE OF ADHERENT CELLS WITH STIRRING | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 18737066 | PROTOCOL GENERATING TISSUE SPECIFIC ENDOTHELIAL CELL LINE, NAMED LIOVECS (LUNG TISSUE IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELL) AND BIOVECS (BLOOD VESSEL STEM CELL IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELLS) | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18124656 | HUMAN FACILITATING CELLS | Final Rejection | University of Louisville Research Foundation, Inc. |
| 18002633 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS | Final Rejection | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy51.2% of resolved applications examined by Taeyoon Kim were allowed (901 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.
This examiner's interview lift is +52.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Taeyoon Kim took 1,382 days on average from filing to allowance.
Taeyoon Kim examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).